

## **TABLE OF CONTENTS**

<b>Appendix Figure Legends</b>	<b>1–5</b>
<b>Appendix References</b>	<b>7</b>
<b>Appendix Figures</b>	
Appendix Figure S1	
Appendix Figure S2	
Appendix Figure S3	
Appendix Figure S4	
Appendix Figure S5	
Appendix Figure S6	
Appendix Figure S7	
Appendix Figure S8	
Appendix Figure S9	
Appendix Figure S10	
Appendix Figure S11	
Appendix Figure S12	
Appendix Figure S13	
<b>Appendix Tables</b>	
Appendix Table S1	
Appendix Table S2	
Appendix Table S3	
Appendix Table S4	

## APPENDIX FIGURE LEGENDS

### Appendix Figure S1. Reciprocal IP confirmed AMBRA1-VIF interaction

N-terminally or C-terminally FLAG-tagged AMBRA1 and empty vector or Strep-tagged HIV-1 constructs were co-transfected in HEK293T cells and subjected to FLAG IP. IP and input lysates were analyzed by immunoblot. Asterisk denotes non-specific bands.

### Appendix Figure S2. AMBRA1 depletion enhances HIV-1 infectivity

Similar to Figure 2, human primary CD4<sup>+</sup> T cells with *AMBRA1* knockout using Cas9 RNPs were infected with HIV-1 NL4-3 IRES-GFP reporter virus that resulted in 2% infectivity in the NT cells. Infectivity was measured by flow cytometry 48 h post-infection. Pair-wise comparisons between NT and the gene of interest were carried out by Mann-Whitney-Wilcoxon Test (\**p*-value < 0.05). Bar graph represents mean + SEM, n=3.

### Appendix Figure S3. AMBRA1-knockout HEK293T cells generated with the CRISPR-Cas9 system

- A Cartoon depicts the AMBRA1 sgRNA-targeting region. Red, sgRNA sequence; blue, the PAM.
- B HEK293T cells transfected with the AMBRA1 sgRNA-encoding plasmid (cloned into SpCas9-P2A-GFP, Addgene #48138) for 48–72 h were FACS-sorted into tubes based on GFP expression. Expanded polyclonal AMBRA1 knockout (KO) and parental HEK293T cells were analyzed by immunoblot.
- C Alignment of the sequence reads from parental and AMBRA1 KO #4 HEK293T cells (clonally selected from AMBRA1 sgRNA-transfected HEK293T cells) encompassing

human AMBRA1 exon2. “-” denotes deletion of nucleotides. Of note, AMBRA1 KO #2 cells (also edited with the same AMBRA1 sgRNA) may contain a large insertion/deletion that could not be amplified with the same set of PCR primers.

**Appendix Figure S4. APOBEC3G degradation by CRL5<sup>VIF</sup> is upregulated in an AMBRA1-depleted background**

- A, B Co-expression of HA-tagged APOBEC3G (A3G), increasing amounts of Strep-tagged VIF, and transfection control GFP in parental HEK293T, AMBRA1 knockout (KO) cells #2 (A) or KO #4 (B). The total amount of transfected DNA was kept constant by adding empty vector. Lysates were analyzed by immunoblot. Asterisk denotes non-specific bands.
- C Similar to described in (B), but included empty vector control or re-expression of AMBRA1 in AMBRA1 KO #4 background.
- D Similar co-transfection experiment was carried out with empty vector control, FLAG-ELOC, or co-expression of FLAG-ELOC and FLAG-ELOB.

**Appendix Figure S5. Removal of predicted N-terminal helical region of AMBRA1 resulted in both gain and loss of protein-protein interactions**

- A Predicted secondary and tertiary structures of AMBRA1. Upper panel depicts alignment of AMBRA1 N-terminal sequence with other DCAFs (Robert & Gouet, 2014). The structure of DDB2 in complex with DDB1 was used as a template to represent the conserved motif (PDB ID: 3EI4). Lower panel shows a homology model of the AMBRA1 N-terminal region encompassing a helical region important for DDB1 binding and a partial WD40 domain, generated by SWISS-MODEL using human DNA excision repair protein ERCC-8 (CSA/ERCC8) as a template (Biasini *et*

*al*, 2014). Red colored residues denote breakpoints for generating  $\Delta$ H22,  $\Delta$ H34, and  $\Delta$ H43 AMBRA1 mutants.

- B Volcano plot showing gain (red) and loss (blue) of interactions by  $\Delta$ H22 mutant versus WT AMBRA1 in three independent AP-MS experiments (also see Figure 3C).
- C, D Bar graphs showing the abundance of purified/co-purified proteins with (C) and without (D) VIF expression, represented by integrated peak intensity from the parental-ion mass analysis using MaxQuant. Statistical analysis of paired comparison was carried out using MSstats (Choi *et al*, 2014) (*p*-values \* < 0.05; \*\* < 0.01; \*\*\*\* < 0.0001; n.s. not significant). Note that CUL4A was not detected in  $\Delta$ H43 AP-MS in the presence of VIF (C).

#### **Appendix Figure S6. Binding specificity of AMBRA1 for ELOC and not SKP1**

- A Alignment of ELOC and SKP1 amino acid sequences.
- B Parental or stable HEK293T cells expressing FLAG-tagged ELOC or SKP1 were purified with anti-FLAG beads. IP and input lysates were examined by immunoblot.

#### **Appendix Figure S7. Mapping AMBRA1 and ELOC interacting regions**

- A WT AMBRA1 and its deletion mutants were expressed in HEK293T cells, followed by lysis and IP.
- B Scheme of the AMBRA1 deletion constructs used in (A). The ability of these mutants to interact with DDB1 is annotated by + and – signs.
- C WT ELOC and the 1–90 mutant were expressed in HEK293T cells and were immunoprecipitated using anti-FLAG beads. The input lysate and IP samples were analyzed by immunoblot. EV stands for empty vector and FL stands for full-length ELOC (amino acids 1–112).

**Appendix Figure S8. ELOC, not ELOB, shows MG132- and ubiquitin K48-dependent polyubiquitination**

- A HEK293T cells stably expressing FLAG-ELOB or FLAG-ELOC were transfected with myc-ubiquitin or empty vector, followed by DMSO or MG132 treatment and denaturing IP. IP and input lysates were examined by immunoblot.
- B ELOC polyubiquitination is accumulated by proteasomal inhibition and reduced by K48R ubiquitin mutation. Denaturing IP of ELOC was performed on HEK293T cells stably expressing FLAG-ELOC transfected with WT or K48R myc-ubiquitin. Before harvested for IP, cells were treated with DMSO control or 5  $\mu$ M MG132 for 6 hours. IP and input lysates were examined by immunoblot.

**Appendix Figure S9. ELOC is a ubiquitination substrate targeted by CRL4<sup>AMBRA1</sup>**

FLAG-ELOC-expressing HEK293T cells were pre-treated with 10 nM of NT or AMBRA1 siRNA, followed by MG132 treatment and denaturing IP. IP and input lysates were examined by immunoblot.

**Appendix Figure S10. AMBRA1 knockdown does not affect the mRNA expression of ELOB and ELOC**

HEK293 cells stably expressing NT or the indicated AMBRA1 shRNA were measured for expression of *AMBRA1*, *ELOB*, and *ELOC* using qPCR. Relative mRNA expression was normalized against the house-keeping gene *GAPDH* and plotted in ratio relative to the NT control.

**Appendix Figure S11. Confirmation of ATG- and CUL4A-knockout HEK293T clones**

- A, B CUL4A-knockout HEK293T cells were confirmed by the protein depletion via immunoblot (A) and genomic DNA PCR of the targeting region (B). Clone#36 was used in Figure 5D. Asterisks denote nonspecific bands.
- C Functional validation of ATG7- and ATG12-knockout HEK293T cells. Lysates from control, ATG7-, and ATG12-knockout clonal HEK293T cells were analyzed by immunoblot. ATG7- and ATG12-knockout were verified by the protein depletion and the accumulation of p62/SQSTM1 as a result of autophagy deficiency.
- D Genotyping data of the CRISPR-Cas9-mediated ATG-knockout cell lines used in this study. Red, single-chimeric guide RNA (sgRNA) sequences; blue, photospacer-associated motifs (PAMs). “-” denotes deletion of nucleotides; “\*” indicates insertion of nucleotides (highlighted in bold italics).

#### **Appendix Figure S12. VIF is stabilized by blocking its autocatalysis**

Expression of VIF-GFP and VIF L145A-GFP in HEK293 cells was induced by the addition of 1  $\mu\text{g}/\text{mL}$  dox for 16 hours, followed by the addition of 100  $\mu\text{g}/\text{mL}$  of CHX at different time points. Lysates were analyzed by immunoblot.

#### **Appendix Figure S13. Substrate-shielding effect**

- A Increased CBF $\beta$  polyubiquitination by VIF overexpression. HEK293T cells co-expressing FLAG-tagged CBF $\beta$ , myc-ubiquitin along with empty vector, or Strep-tagged VIF were affinity purified under denaturing conditions with anti-FLAG to examine ubiquitin incorporation into CBF $\beta$ . IP and input lysates were analyzed by immunoblot. Note that a trace amount of FLAG antibody light chain detected in the IP eluates masks Strep immunodetection.
- B Model depicting substrate-shielding effect. VIF is sensitive to autoubiquitination in

the absence of its binding partner CBF $\beta$  and the VIF substrate APOBEC3.


## APPENDIX REFERENCES



Biasini M, Bienert S, Waterhouse A, Arnold K, Studer G, Schmidt T, Kiefer F, Gallo Cassarino T, Bertoni M, Bordoli L, Schwede T (2014) SWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information. *Nucleic Acids Res* 42: W252-8



Choi M, Chang C-Y, Clough T, Broudy D, Killeen T, MacLean B, Vitek O (2014) MSstats: an R package for statistical analysis of quantitative mass spectrometry-based proteomic experiments. *Bioinformatics* 30(17): 2524-2526

Robert X, Gouet P (2014) Deciphering key features in protein structures with the new ENDscript server. *Nucleic Acids Research* 42: W320-W324











**A****B****C**

WT: ATGGGAGCTCAGCGGCTTCTGCAGGAGCTGGTAGAAGATAAAAACCCGGTGGATGAAATGGGAG  
 AMBRA1 KO#4-1: ATGGGAGCTCAGCGGCTTCTGCAGGAGC-----CGGTGGATGAAATGGGAG  
 AMBRA1 KO#4-2: ATGGGAGCTCAGCGGCTTCTGCAGGAGC-----CGGTGGATGAAATGGGAG  
 AMBRA1 KO#4-3: ATGGGAGCTCAGCGGCTTCTGCAGGAGC-----CGGTGGATGAAATGGGAG  
 AMBRA1 KO#4-4: ATGGGAGCTCAGCGGCTTCTGCAGGAGCTGGTAGAAGATAAAAACC-GGTGGATGAAATGGGAG  
 AMBRA1 KO#4-5: ATGGGAGCTCAGCGGCTTCTGCAGGAGCTGGTAGAAGATAAAAACC-GGTGGATGAAATGGGAG  
 AMBRA1 KO#4-6: ATGGGAGCTCAGCGGCTTCTGCAGGAGCTGGTAGAAGATAAAAACC-GGTGGATGAAATGGGAG  
 AMBRA1 KO#4-7: ATGGGAGCTCAGCGGCTTCTGCAGGAGCTGGTAGAAGATAAAAACC-GGTGGATGAAATGGGAG  
 AMBRA1 KO#4-8: ATGGGAGCTCAGCGGCTTCTGCAGGAGCTGGTAGAAGATAAAAACC-GGTGGATGAAATGGGAG


**A****B****C****D**



**A**




SKP1_HUMAN	1	.....MPSIKLQSSDGEIFE
ELOC_HUMAN	1	MDGEEKTYGGCEGPDAMYVKLISSDGHEFI
consensus>70		.....!KL.SSDG..F.
SKP1_HUMAN	16	V D V E I A K Q S V T I K T M L E D L G M D D E G D D D P V
ELOC_HUMAN	31	V K R E H A L I S G T I K A M L S G P G Q F A E N E T N E V
consensus>70		V..E.A..S.TIK.ML...G...E.#.#.V
SKP1_HUMAN	46	PLPNVNAAILKQVIQWCTHHKDDPPPPEDD
ELOC_HUMAN	61	NFREIPSHVLSKVCMYFTYKV.....RY
consensus>70		...#!...!L.KV....T.....
SKP1_HUMAN	76	ENKEKRTDIPVWDQEFKVDQGTLELIL
ELOC_HUMAN	84	TNSSTEIPEFPIAPE.....IA.LELLM
consensus>70		.N.....#.P!..#.....EL.\$
SKP1_HUMAN	106	AANYLDIKGLLDVTCKTVANMIKGTPEEI
ELOC_HUMAN	106	AANFLDC.....
consensus>70		AAN%LD.....
SKP1_HUMAN	136	RKTFNIKNDFTEEEEEAQVRKENQWCEEK
ELOC_HUMAN		.....
consensus>70		.....



**B**




**A**


AMBRA1 truncated mutants (FLAG-tagged)


**B****C**

**A****B**








**A****B**Genomic PCR on genomic locus of *cul4a* on Chromosome 13**C**


WT: CTGCCAGCTATTGGAACACTGTATAACACCAACACACTCGAGTCTTTCAAG<sup>PAM</sup>ACTGCAGATAA  
 ATG7 KO#1-1: CTGCCAGCTATTGGAACACTGTATAACACCA--ACACTCGAGTCTTTCAAGACTGCAGATAA  
 ATG7 KO#1-2: CTGCCAGCTATTGGAACACTGTATAACACCA--ACACTCGAGTCTTTCAAGACTGCAGATAA  
 ATG7 KO#1-3: CTGCCAGCTATTGGAACACTGTATAACACCAACAC-----CAAGACTGCAGATAA


WT: CTGCCAGCTATTGGAACACTGTATAACACCAACACACTCGAGTCTTTCAAG<sup>PAM</sup>ACTGCAGATAA  
 ATG7 KO#2-1: CTGCCAGCTATTGGAACACTGTATAA-----AGACTCGAGTCTTTCAAGACTGCAGATAA  
 ATG7 KO#2-2: CTGCCAGCTATTGGAACACTGTATAA-----AGACTCGAGTCTTTCAAGACTGCAGATAA  
 ATG7 KO#2-3: CTGCCAGCTATTGGAA-----AGACTCGAGTCTTTCAAGACTGCAGATAA  
 ATG7 KO#2-4: CTGCCAGCTATTGGAA-----AGACTCGAGTCTTTCAAGACTGCAGATAA

WT: TGTCTCCCAGAAACAACCACCCCGGAGCCCCCGTCTTCCGCTGCAGTTT<sup>PAM</sup>CCCCGGGAACAGA  
 ATG12 KO#2-1: TGTCTCCCAGAAACAACCACCCCGGAGCCCCCG--TTCCGCTGCAGTTTCCCCGGGAACAGA  
 ATG12 KO#2-2: TGTCTCCCAGAAACAACCACCCCGGAGCCCCCG--TTCCGCTGCAGTTTCCCCGGGAACAGA  
 ATG12 KO#2-3: TGTCTCCCAGAAACAACCACCCCGGAGCCCCCG--TTCCGCTGCAGTTTCCCCGGGAACAGA  
 ATG12 KO#2-4: TGTCTCCCAGAAACAACCACCCCGGAGCCCCCG\*TCTTCCGCTGCAGTTTCCCCGGGAACAGA  
 & #2-5~#2-7: **GCTGCAAAGTTTCTTCAATGGCCACGAGCCATCCCCAGGAGAACACACAGTTGAAGGGGCACC**  
**AGCCCCTGCTTCTCTGCTGCAAAGTGAGCCAGATAACCAGGAAAACCAGATCAATCCTCTGGT**  
**CAAGGTACAGCAGGAAGTCAAGGCTGCTGCAGAAGTGAACACTCACTCAGGAGTTCTGGAGCTGAC**  
**TCTGGCTAGTCCCAGTCAACAGAGCA**

WT: TGTCTCCCAGAAACAACCACCCCGGAGCCCCCGTCTTCCGCTGCAGTTT<sup>PAM</sup>CCCCGGGAACAGA  
 ATG12 KO#2-1: TGTCTCCCAGAAACAACCACCCCGGAGCCCCCGTATCTTCCGCTGCAGTTTCCCCGGGAACAGA  
 ATG12 KO#2-2: TGTCTCCCAGAAACAACCACCCCGGAGCCCCCGTATCTTCCGCTGCAGTTTCCCCGGGAACAGA  
 ATG12 KO#2-3: TGTCTCCCAGAAACAACCACCCCGGAG-----CCGCTGCAGTTTCCCCGGGAACAGA  
 ATG12 KO#2-4: TGTCTCCCAGAAACAACCACCCCGGAG-----CCGCTGCAGTTTCCCCGGGAACAGA  
 ATG12 KO#2-5: TGTCTCCCAGAAACAACCACCCCGGAG-----CCGCTGCAGTTTCCCCGGGAACAGA  
 ATG12 KO#2-6: TGTCTCCCAGAAACAACCACCCCGGAG-----CCGCTGCAGTTTCCCCGGGAACAGA

**D**





## Appendix Table S1

Key recombinant DNA constructs used in this study

<b>Recombinant DNA</b>	<b>Vector</b>
FLAG-ELOC	pCDH-EF1-MCS-IRES-GFP (SBI)
FLAG-SKP1	pCDH-EF1-MCS-IRES-GFP (SBI)
SOCS3-GFP	Tet-On 3G ZeoR (Clontech)
VIF-GFP	Tet-On 3G ZeoR (Clontech)
VHL-GFP	Tet-On 3G ZeoR (Clontech)
PPIL5-GFP	Tet-On 3G ZeoR (Clontech)
AMBRA1-FLAG	Tet-On 3G ZeoR (Clontech)
AMBRA1 $\Delta$ 34H-FLAG	Tet-On 3G ZeoR (Clontech)
mCherry-FLAG	pCDH-EF1-MCS-T2A-HygroR (SBI)
AMBRA1-FLAG	pCDH-EF1-MCS-T2A-HygroR (SBI)

## Appendix Table S2

Guide RNA sequences used in HIV-1 infection in primary T cells

crRNA	target gene	Guide sequence
AMBRA1-06	AMBRA1	TGGTAGAAGATAAAACCCGG
AMBRA1-07	AMBRA1	AGAATGCTGTCCGGATACTC
AMBRA1-08	AMBRA1	AAGGTAGAGCGTGGACTATC
NT	non-targeting	TCGGATGTAAATTATGCCGT
CXCR4	CXCR4	GAAGCGTGATGACAAAGAGG

## Appendix Table S3

The following table includes RNAi-based sequences, sgRNA sequences for CRISPR-Cas9-mediated gene knockout, and primers used to PCR amplify the edited regions.

Sequence-Based Reagents	SOURCE	IDENTIFIER
pLKO.1 Control sh-NT	Sigma-Aldrich	SHC002
pLKO.1 sh-AMBRA1 #1; target GGCTTGGCCTATGGTACTAAC	Sigma-Aldrich	TRCN0000417120
pLKO.1 sh-AMBRA1 #2; target GGCCACTGGGAAAGAATTTAC	Sigma-Aldrich	TRCN0000441636
pLKO.1 sh-AMBRA1 #3; target CCCACCTTCTCCTAGTAACAT	Sigma-Aldrich	TRCN0000167886
si-AMBRA1; UUUGUUAGUACCAUAGGCCAAGCCA	Thermo	pre-designed Stealth#3156
si-ELOB; GCUGUACAAGGAUGACCAAtt	This paper	NA
si-ELOC; CGAACUUCUUAGAUUGUUAtt	This paper	NA
si-CUL5; AGCUGAUUCAGUUAUAUAtt	This paper	NA
si-SOCS3	Sigma-Aldrich	pre-designed SASI_Hs01_00179195
si-Control	Thermo	Stealth siRNA negative control medium GC, Cat#12935300
si-DDB1 #2	Dharmacon	J-012890-07-0002
si-DDB1 #3	Dharmacon	J-012890-08-0002
si-DDB1 #4	Dharmacon	J-012890-09-0002
si-CUL4B	Dharmacon	J-017965-05-0002
SpCas9-P2A-GFP AMBRA1 sgRNA TGGTAGAAGATAAAACCCGG	This paper	NA
SpCas9-P2A-puro ATG7 ATAGCTGGGCAGCAACGGGC	This paper	NA
SpCas9-P2A-puro ATG12 GAAACTGCAGCGGAAGACGG	This paper	NA
CUL4A sgRNA CGGCGGTTCCGGCCCAGCC	This paper	NA
AMBRA1 genotyping forward primer tagaactagtgatccCTTCTCGTTGCAGAAGTCGT	This paper	NA
AMBRA1 genotyping reverse primer gcttgatcgatcCAGATATGTCAACTCTCCCACACA	This paper	NA
ATG7 genotyping forward primer caccg TGGGGGACAGTAGAACAGCA	This paper	NA
ATG7 genotyping reverse primer aaac CCTGGATGCCTCTCCCTGA	This paper	NA
ATG12 genotyping forward primer caccgAGCCGGGAACACCAAGTTT	This paper	NA
ATG12 genotyping reverse primer aaacGTGGCAGCCAAGTATCAGGC	This paper	NA
CUL4A editing site forward primer GAGGGGGTGTCCGAATCTCT	This paper	NA
CUL4A editing site reverse primer GCTCCTCGAGATGGTCCACT	This paper	NA



## Appendix Table S4

Antibodies used in this study

<b>Antibodies</b>	<b>SOURCE</b>	<b>IDENTIFIER</b>
Rabbit polyclonal anti-AMBRA1	EMD-Millipore	ABC131
Rabbit polyclonal anti-AMBRA1	Bethyl	A302
Mouse monoclonal anti-ELOC	BD Biosciences	#610761
Rabbit monoclonal anti-ELOB	Abcam	ab154854
Rabbit monoclonal anti-CUL4A	Abcam	ab92554
Rabbit polyclonal anti-CUL4B	Sigma-Aldrich	SAB2107673
Mouse monoclonal anti-DDB1	Thermo Fisher	#39-9901
Mouse monoclonal anti-STAT3	Cell Signaling Technology	#9139
Rabbit monoclonal anti-Phospho-STAT3 (Tyr705)	Cell Signaling Technology	#9145
Rabbit polyclonal anti-SOCS3	Cell Signaling Technology	#2932
Rabbit polyclonal anti-GAPDH	Cell Signaling Technology	#2118
Mouse monoclonal anti-GAPDH	Thermo Fisher	MA5-15738
Rabbit polyclonal anti-GFP	Abcam	ab6556
Mouse monoclonal anti-GFP	Santa Cruz	sc9996
Mouse monoclonal anti-HA	Cell Signaling Technology	#2367
Rabbit polyclonal anti-Myc	Abcam	ab9106
Guinea pig polyclonal anti-p62/SQSTM1	Progen	GP62-C
Mouse monoclonal anti-p62/SQSTM1	Novus	#2C11
Rabbit polyclonal anti-LC3	EMD-Millipore	ABC232
Goat polyclonal anti-ATG7	Santa Cruz	sc8668
Rabbit polyclonal anti-ATG12	Cell Signaling Technology	#4180